Other Events ·
NYSE American notifies Calidi of non-compliance with stockholders’ equity listing standard, requiring $4.0 million in equity
CLDWWCalidi Biotherapeutics, Inc.
Calidi Biotherapeutics received a notice from NYSE American on September 21, 2026, stating it is not in compliance with the stockholders’ equity continued listing standard. The exchange requires $4.0 million in equity for companies reporting losses in three of four recent fiscal years; Calidi reported $3.1 million as of June 30, 2026. The company must submit a compliance plan by October 21, 2026, to regain compliance by March 21, 2028. Failure to submit or accept the plan triggers delisting proceedings. Trading continues under symbol CLDI with a “.BC” indicator. Calidi Biotherapeutics is a biotechnology company developing targeted genetic medicines using its RedTail platform.